Equillium
Biotechnology, 2223 Avenida De La Playa Ste 105, San Diego, California, 92037, United States, 11-50 Employees
Phone Number: 85********
Who is EQUILLIUM
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients wit...
Read More
-
Headquarters: 2223 Avenida De La Playa Ste 105, San Diego, California, 92037, United States
-
Date Founded: 2017
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Equillium Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Equillium
Answer: Equillium's headquarters are located at 2223 Avenida De La Playa Ste 105, San Diego, California, 92037, United States
Answer: Equillium's phone number is 85********
Answer: Equillium's official website is https://equilliumbio.com
Answer: Equillium's revenue is $1 Million to $5 Million
Answer: Equillium's SIC: 2836
Answer: Equillium's NAICS: 325414
Answer: Equillium has 11-50 employees
Answer: Equillium is in Biotechnology
Answer: Equillium contact info: Phone number: 85******** Website: https://equilliumbio.com
Answer: Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs. By bringing treatments designed to restore the balance of the immune system, we hope to restore the balance of life for patients in need. Our lead product candidate, itolizumab, is a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the activation and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. We believe itolizumab may have broad therapeutic utility and our current pipeline is focused on developing itolizumab as a best-in-class treatment for multiple severe immuno-inflammatory disorders this includes acute graft-versus-host disease, SLE / lupus nephritis and uncontrolled asthma.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month